- Cisco Ups Tandberg Bid, Claims Over 40% Backing
- 'Significant Weakness' Still Ahead: Fed's Hoenig
- BlackRock: Central Banks To Be Net Buyers of Gold
- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Washington Not Trying to Contain China: Obama
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Quiz: How Much Do You Know About Green?
- JP Morgan to Bid Over $3 Billion for Cazenove Stake
- Buffett: I Haven't Bought AMEX Shares in Years
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
MOST SHARED
- U.S. May Wind Up Green With Envy
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Taking a Page from Obama's Asia Agenda in Investing
- The Cost of Thanksgiving Dinner 2009
- EADS Cautious on Full-Year Forecast after Earnings Dip
- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Sustainability Indices Sprouting Up
- JP Morgan to Bid Over $3 Billion for Cazenove Stake
Text Size 
German drugs and chemicals company Merck KGaA reported a 15 percent rise in second-quarter operating profit on Wednesday thanks to rising sales of liquid crystals and multiple-sclerosis and cancer drugs.
Operating profit rose to 320.5 million euros ($510 million) from 277.5 million euros a year earlier, slightly missing the average estimate of 326 million euros in a Reuters poll of 15 analysts.
"Currency effects continued to have a considerable negative impact on total revenues," the company said in a statement.
Merck KGaA said total revenues grew organically by 12 percent but this was reduced by 6.1 percentage points due to translation of local currencies into the strong euro.
Sales of its cancer medicine Erbitux rose 24 percent in the second quarter, while sales of its multiple-sclerosis drug Rebif increased 2.8 percent.
Merck KGaA is also the world's largest supplier of the liquid crystal compounds used in televisions, mobile phones and computer laptops.
Liquid crystals sales rose 7 percent to 238 million euros, despite negative currency effects.
The operating profit margin for this business dipped to 45 percent in the quarter.
For 2008, Merck reiterated it expected group revenue to grow 5-9 percent and its operating margin -- excluding amortization and integration costs -- to be 23-27 percent.
Merck KGaA shares have fallen about 10 percent this year, roughly in line with the pan-European DJ Stoxx chemicals index and the drugs sector index, partly on worries over the impact of a slowdown in the U.S. economy.
According to Reuters data, Merck shares trade at 16 times estimated 2009 profit, a premium to the chemicals and drugs sectors' 12 times thanks partly to upbeat outlook for Erbitux.
Print
Email
- Where, what, how.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
Data is a real-time snapshot *Data is delayed at least 15 minutes